Trial Profile
Multicenter, Randomized, Controlled Study to Evaluate the Efficacy of Thymosin alpha1 in Patients With Severe Sepsis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Thymalfasin (Primary)
- Indications Sepsis
- Focus Therapeutic Use
- Acronyms ETASS
- 13 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jul 2010 Planned end date changed from 1 Jan 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
- 05 Jun 2009 New trial record